智通财经APP获悉，周三，百济神州(ONC.US)涨逾3%，报252.97美元。据了解，随着国内创新药企业研发实力的提升，越来越多的企业开始走向国际市场。尤其，中国创新药License-out(对外授权)交易额激增，2024年海外授权首付款31.6亿美元，交易总额511亿美元，联邦制药、恒瑞医药等多笔大额授权刷新纪录，全球BD交易占比升至30%。2025年一季度，海外授权总额再创455亿美元纪录，并且已经接近2024年全年水平。
另外，7月1日，国家医保局联合国家卫生健康委出台《支持创新药高质量发展的若干措施》，再次强调了对于创新药的全方位政策支持，并且将商保纳入制度框架，打开创新药的长期支付空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.